Glycerin

Evidence Level: L5

Predicted Indications: 10

Glycerin

Pharmacist Assessment Report

Glycerin: Cauda equina syndrome

One-Sentence Summary

Glycerin is an osmotic agent, originally used to treat constipation. The TxGNN model’s top-ranked prediction is cauda equina syndrome, but no clinical trials and no publications currently support it. The best-supported alternative among the top 10 predictions is open-angle glaucoma, which has only indirect, low-level literature (3 publications, none showing efficacy).

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	Cauda equina syndrome
TxGNN Prediction Score	0.9960
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products	at least 20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, glycerin is a hyperosmotic agent. Its efficacy in constipation is established, as it draws water into the bowel lumen.

For cauda equina syndrome, no mechanistic link has been identified. The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. There is no supporting clinical or literature evidence, so the prediction should be treated as a hypothesis only.

Other predictions in the top 10 are also weak:

Open-angle glaucoma (0.9959, L4): Oral glycerin has a historical role as a hyperosmotic agent that lowers intraocular pressure, which gives a plausible indirect rationale. However, it was used mainly for acute angle-closure episodes rather than chronic open-angle glaucoma. The retrieved papers address closed-angle glaucoma pathogenesis, glycerin-preserved corneoscleral grafts, and osmoprotection in dry eye, and none supports efficacy.
Irritable bowel syndrome (0.9949, L4): Glycerin’s osmotic laxative action gives indirect relevance to constipation-predominant IBS. The literature is weak, a 1964 commentary and an unrelated nanoemulsion paper.
Alopecia, hypotrichosis and alopecia areata variants, migraine and migraine with brainstem aura, primary hereditary glaucoma: prediction only, with no credible mechanistic rationale.

Clinical Trial Evidence

Currently no related clinical trials registered for cauda equina syndrome or for any of the other top 10 predicted indications.

Literature Evidence

No literature is available for cauda equina syndrome. The table below lists the most relevant retrieved publications for the next-ranked predictions. None demonstrates a therapeutic effect of glycerin in the predicted condition.

PMID	Year	Type	Journal	Key Findings
1614157	1992	Review	Klin Monatsbl Augenheilkd	Pathogenesis and treatment of primary closed-angle glaucoma (not open-angle)
32890110	2020	Case series	J Glaucoma	Glycerin-preserved donor corneoscleral patch grafts are safe and effective for glaucoma drainage devices (tissue preservation use)
20872359	2011	Clinical study	Eur J Ophthalmol	Osmoprotective artificial tears and ocular surface damage in glaucoma patients on topical therapy
14215532	1964	Review/commentary	JAMA	“Irritable colon” clinical commentary (no abstract)
3896179	1985	Double-blind RCT	Arch Intern Med	Polysorbate 60 was ineffective in male pattern baldness; glycerin served as the control
14555416	2003	Safety review	Int J Toxicol	Safety assessment of triacetin (glyceryl triacetate), a different compound

India Market Information

Glycerin has 20 valid single-ingredient registrations, all injectable or infusion products. Approved indication text is not recorded for these registrations. The five main ones are listed below.

Authorization Number	Product Name	Dosage Form	Approved Indication
154076	Newtol 100ml Infusion	Bottle of 100 ml infusion	Not specified
144415	Megtil 10gm/10gm Infusion	Bottle of 100 ml infusion	Not specified
38730	Chemitol Injection	Bottle of 100 ml injection	Not specified
99961	Glycerim 10gm/10gm Infusion	Bottle of 100 ml infusion	Not specified
98270	Grapitol G 10mg/10mg Infusion	Vial of 100 ml infusion	Not specified

Safety Considerations

Package insert warnings and contraindications were not available for this report, so please refer to the package insert for safety information.

Drug Interactions: The interaction screen identified 220 potential interacting drugs. The list available here includes mostly moderate-level interactions, for example:

Abiraterone, tramadol, acetazolamide, hydrocortisone, salbutamol
Alfuzosin, hydrochlorothiazide, amiloride, amiodarone, amisulpride
Benazepril, anagrelide, propofol, apalutamide, apomorphine
Triamcinolone, arsenic trioxide, lumefantrine, asenapine

Doxycycline is the one listed minor interaction. Clinical significance should be checked for each specific combination.

Conclusion and Next Steps

Decision: Hold

Rationale: The top prediction, cauda equina syndrome, rests only on a score from the TxGNN model (deep learning), which may reflect similarities the model learned between related diseases, not biological evidence. There are no trials, no literature, and no mechanistic link. Even the more plausible candidates (open-angle glaucoma, IBS) lack supporting efficacy evidence. The India market is well established, but the registered products are all injectable or infusion forms and have no recorded indication text.

To proceed, the following is needed:

Mechanism of action data for glycerin
Package insert warnings and contraindications for the Indian products
A defined mechanistic hypothesis and preclinical or clinical evidence for any selected indication, with glaucoma (IOP lowering) as the most plausible starting point
Confirmation that the registered injectable and infusion routes are compatible with the intended use, since route compatibility has not been assessed
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.